Home   >  
Neuro Signaling Pathway
  • Others Pathway
  >  
Monoamine Oxidase
  • Autophagy
  >   Rasagiline mesylate
Rasagiline mesylate Chemical Structure

Rasagiline mesylate

Data Sheet For research use only. Not for human use.
Cat. No. :BCP05224CAS No. :161735-79-1Purity:98%
 Tel: 0086-17754423994   or   orders@biochempartner.com
Real-Time Inquiry ×

* Required Fields.

Please complete the form below and you will get the price list in 1 minute.

Product name

 

* Applicant name

Catalog Number

 

* Institution/Company

* Email address

 

Phone number

Country

 

* Quantity Required

Remarks

Inquiry Online ×

* Required Fields.

Please complete the form below and we will contact you shortly.

Product name

 

* Applicant name

Catalog Number

 

* Institution/Company

* Email address

 

Phone number

Country

 

* Quantity Required

Remarks

Bulk Inquiry ×

* Required Fields.

Please complete the form below and we will contact you shortly.

Product name

 

* Applicant name

Catalog Number

 

* Institution/Company

* Email address

 

Phone number

Country

 

* Quantity Required

Remarks

  • Chemical Properties&Biological Activity
CAS No. 161735-79-1 Cat. No. BCP05224
Related Products 136236-51-6(Rasagiline)
Name Rasagiline mesylate
Synonyms AGN1135; TVP1012;AGN-1135; TVP-1012;AGN 1135; TVP 1012;
SMILES CS(=O)(=O)O.C#CCNC1CCC2=CC=CC=C12
Chemical Name
Formula C13H17NO3S M. Wt 267.34
Purity 98% Storage Store at 4-8°C
Description Rasagiline (N-propargyl-1-(R)-aminoindan) is a novel, highly potent irreversible monoamine oxidase (MAO)-B inhibitor, anti-Parkinsonian drug. Rasagiline is effective as monotherapy or adjunct to L-Dopa for patients with early and late Parkinson's disease (PD) . Rasagiline inhibits MAO-B more potently than selegiline and has the advantage of once-daily dosing. In several large, randomized, placebo-controlled trials, rasagiline has demonstrated efficacy as monotherapy in early PD and as adjunctive therapy in advanced PD. In addition, rasagiline has been shown to have neuroprotective effects in in vitro and in vivo studies. The recently completed delayed-start ADAGIO (Attenuation of Disease Progression with Azilect Given Once-daily) trial suggests a potential disease-modifying effect for rasagiline 1 mg/day, though the clinical import of this finding has yet to be established .
  • Quality Control&Technical Support
In the process of purchasing and using Biochempartner products, you can consult us if you have any problems: orders@biochempartner.com. We will try our best to solve all your doubts.

Recommend Products

More >

Tags:Rasagiline mesylate supplier,Rasagiline mesylate purchase,Rasagiline mesylate manufacturer,Rasagiline mesylate distributor,Rasagiline mesylate cost,Rasagiline mesylate buy,Rasagiline mesylate for sale

0086-13720134139